Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1965 1
1968 1
1970 1
1971 2
1972 6
1973 18
1974 15
1975 30
1976 35
1977 29
1978 16
1979 18
1980 20
1981 24
1982 14
1983 22
1984 15
1985 11
1986 15
1987 17
1988 13
1989 9
1990 19
1991 22
1992 5
1993 13
1994 6
1995 12
1996 6
1997 6
1998 12
1999 7
2000 18
2001 8
2002 14
2003 32
2004 40
2005 44
2006 50
2007 71
2008 52
2009 64
2010 92
2011 113
2012 145
2013 135
2014 144
2015 185
2016 225
2017 281
2018 382
2019 572
2020 830
2021 94
Text availability
Article attribute
Article type
Publication date

Search Results

3,601 results
Results by year
Filters applied: . Clear all
Page 3
The Utility of Cannabidiol in the Treatment of Refractory Epilepsy.
Reddy DS. Reddy DS. Clin Pharmacol Ther. 2017 Feb;101(2):182-184. doi: 10.1002/cpt.441. Epub 2016 Sep 29. Clin Pharmacol Ther. 2017. PMID: 27506704 Review.
Cannabis-derived cannabinoids such as cannabidiol (CBD) have anticonvulsant properties. Recently, there has been an emerging interest in the use of CBD-enriched products for treatment of drug-resistant epilepsy. ...
Cannabis-derived cannabinoids such as cannabidiol (CBD) have anticonvulsant properties. Recently, there has been an emerging interest …
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Schier AR, et al. Braz J Psychiatry. 2012 Jun;34 Suppl 1:S104-10. doi: 10.1590/s1516-44462012000500008. Braz J Psychiatry. 2012. PMID: 22729452 Free article. Review. English, Portuguese.
OBJECTIVES: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. METHOD: The articles selected for the review were identified through searches in En …
OBJECTIVES: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiol …
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Pina SD, Tambaro S, Memo M, Mastinu A. Premoli M, et al. Life Sci. 2019 May 1;224:120-127. doi: 10.1016/j.lfs.2019.03.053. Epub 2019 Mar 22. Life Sci. 2019. PMID: 30910646 Review.
Among the phytocannabinoids without psychotropic effects, the prevalent one in Cannabis is cannabidiol (CBD). Although CBD was initially considered a type 2 cannabinoid receptor (CB2R) antagonist, it did not show a good cannabinoidergic activity. ...
Among the phytocannabinoids without psychotropic effects, the prevalent one in Cannabis is cannabidiol (CBD). Although CBD was initia …
Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP, Bebin EM. Szaflarski JP, et al. Epilepsy Behav. 2014 Dec;41:277-82. doi: 10.1016/j.yebeh.2014.08.135. Epub 2014 Oct 1. Epilepsy Behav. 2014. PMID: 25282526 Review.
The recent changes in the legal environment have improved the availability of products with high cannabidiol (CBD) and low tetrahydrocannabinol (THC) concentrations. ...
The recent changes in the legal environment have improved the availability of products with high cannabidiol (CBD) and low tetrahydro …
Cannabidiol Claims and Misconceptions.
Russo EB. Russo EB. Trends Pharmacol Sci. 2017 Mar;38(3):198-201. doi: 10.1016/j.tips.2016.12.004. Epub 2017 Jan 12. Trends Pharmacol Sci. 2017. PMID: 28089139
Once a widely ignored phytocannabinoid, cannabidiol now attracts great therapeutic interest, especially in epilepsy and cancer. ...
Once a widely ignored phytocannabinoid, cannabidiol now attracts great therapeutic interest, especially in epilepsy and cancer. ...
Cannabidiol in medical marijuana: Research vistas and potential opportunities.
Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, Mansur RB, Ho RC, McIntyre RS. Rong C, et al. Pharmacol Res. 2017 Jul;121:213-218. doi: 10.1016/j.phrs.2017.05.005. Epub 2017 May 10. Pharmacol Res. 2017. PMID: 28501518 Review.
Herein, we synthesize extant literature pertaining to the phytocannabinoid cannabidiol (CBD) and its brain effects. The principle phytocannabinoid delta(9)-tetrahydrocannabinol (delta(9)-THC) and CBD are the major pharmacologically active cannabinoids. The effect of CBD on …
Herein, we synthesize extant literature pertaining to the phytocannabinoid cannabidiol (CBD) and its brain effects. The principle phy …
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and delta(9)-Tetrahydrocannabinol.
Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Boggs DL, et al. Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209. Epub 2017 Sep 6. Neuropsychopharmacology. 2018. PMID: 28875990 Free PMC article. Review.
There are >550 chemical compounds and >100 phytocannabinoids isolated from cannabis, including delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is thought to produce the main psychoactive effects of cannabis, while CBD does not appear to have similar ef …
There are >550 chemical compounds and >100 phytocannabinoids isolated from cannabis, including delta(9)-tetrahydrocannabinol (THC) and …
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. McGuire P, et al. Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15. Am J Psychiatry. 2018. PMID: 29241357 Clinical Trial.
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. ...
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed th …
[Cannabidiol].
Radbruch L, Häuser W. Radbruch L, et al. Schmerz. 2020 Apr;34(2):115-116. doi: 10.1007/s00482-020-00458-w. Schmerz. 2020. PMID: 32253591 German. No abstract available.
Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S, Kloiber S, Le Foll B. Elsaid S, et al. Prog Mol Biol Transl Sci. 2019;167:25-75. doi: 10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28. Prog Mol Biol Transl Sci. 2019. PMID: 31601406 Review.
Cannabis sativa (cannabis) is one of the oldest plants cultivated by men. Cannabidiol (CBD) is the major non-psychomimetic compound derived from cannabis. ...
Cannabis sativa (cannabis) is one of the oldest plants cultivated by men. Cannabidiol (CBD) is the major non-psychomimetic compound d …
3,601 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page